FDA Approval of Immunotherapy Combo Could Transform Treatment for Some with Advanced Colorectal Cancer

The FDA has approved a nivolumab–ipilimumab combo as a first-line treatment for people with advanced colorectal cancer with MSI-H or dMMR tumors. CU Cancer Center’s Christopher Lieu, MD, an expert in colorectal cancer, noted this approval could lead to improved survival and potential cures, though he emphasized the importance of discussing side effects with patients.